Clinical Trials Directory

Trials / Completed

CompletedNCT01977196

The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma)

Phase 1 of DTP/Hepatitis B 10ug Hib Vaccine

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
30 (actual)
Sponsor
PT Bio Farma · Industry
Sex
All
Age
6 Weeks – 11 Weeks
Healthy volunteers
Accepted

Summary

The objective of this study was to know the safety of DTP/Hepatitis B and Hib/PRP-T vaccine and immediate reactions within the first 30 minutes after injection.

Detailed description

This trial was an open-label study, no randomization, and no placebo or control group. Total 30 healthy infants (age 6-11 weeks) followed this trial. The safety was assessed within 24 hours, 48 hours, 72 hours, and 28 days after injection.

Conditions

Interventions

TypeNameDescription
BIOLOGICALDPT/HepatitisB/Hib vaccineDPT/HepatitisB/Hib vaccine (Bio Farma)

Timeline

Start date
2011-04-01
Primary completion
2011-07-01
Completion
2011-07-01
First posted
2013-11-06
Last updated
2013-11-06

Locations

1 site across 1 country: Indonesia

Source: ClinicalTrials.gov record NCT01977196. Inclusion in this directory is not an endorsement.

The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma) (NCT01977196) · Clinical Trials Directory